Skip to main content

MDL Judge Dismisses 4 Paraquat Cases, Excludes Expert

MDL Judge Dismisses 4 Paraquat Cases, Excludes Expert

MDL Judge Dismisses 4 Paraquat Cases, Excludes Expert

Introduction

The U.S. District Judge overseeing the Paraquat Parkinson’s disease lawsuits has barred a key expert witness from testifying at trial, leading to the dismissal of four bellwether cases lacking the necessary support to proceed.

These cases are part of a larger litigation against Syngenta and Chevron, encompassing over 5,000 lawsuits alleging Paraquat exposure causes Parkinson’s disease. Plaintiffs contend manufacturers failed to sufficiently warn about Paraquat risks during handling.

Expert witnesses were proposed to validate the Paraquat-Parkinson’s link, citing research indicating Paraquat's potential to induce the disease. However, manufacturers refute these assertions, maintaining the herbicide's safety.

All federal Paraquat lawsuits are centralized in the Southern District of Illinois as multidistrict litigation. Bellwether trials, intended to predict jury responses, are crucial components of this process.

During the Paraquat “Daubert” hearings, the Judge evaluated the proposed expert testimony's reliability. Defendants sought the exclusion of an epidemiologist and statistician from Cornell University, pivotal in establishing causation in four bellwether cases.

In a subsequent memorandum and order, the Judge sided with the defendants, excluding the expert testimony due to insufficient evidence linking Paraquat to Parkinson’s disease. As this expert was key to plaintiffs’ causation arguments, all four bellwether trials were dismissed.

This ruling underscores the litigation’s complexity and the challenges associated with proving causation in Paraquat-related Parkinson’s disease cases. While these developments represent setbacks for plaintiffs, the legal process continues, with further proceedings expected in the multidistrict litigation.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!